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Gastric cancer (GC) is one of the most common cancers representing the 
second leading cause of cancer-related mortality. Despite improvements in 
clinical therapies of GC, the recurrence rate of GC patients remains high 
(~55%) with advanced stage of the disease. Therefore, it is essential to 




application for GC diagnosis and prognosis. Here, we aimed to identify 
potential serum biomarkers for recurrence in gastric cancers with an 
established quantitative multiple reaction monitoring (MRM) approach using 
GC patient serum samples. To build up a serum biomarker development 
platform, we first generated serum biomarker candidates through 
comprehensive proteomic approach. By employing both preliminary MRM 
and automated detection of inaccurate and imprecise transitions (AuDIT) 
analysis with stable isotope–labeled internal standard (SIS) peptides using 
pooled GC patient serum samples, we established a quantitative MRM 
analysis of 94 proteins as final MRM target proteins. To establish the multi-
biomarker panel for identification of GC recurrence, we conducted the 
quantitative MRM analysis with 180 individual patients divided into the two 
groups, i.e. response group (n=133) and recurrence group (n=47), who 
received chemotherapy after D2 lymph node dissection in both groups, as a 
training set. By a stringent statistical analysis with quantitative MRM data of 
training set’s individual samples, the 6-marker panel, consisting of alpha-1-
antichymotrypsin (SERPINA3), apolipoprotein A-II (APOA2), 
apolipoprotein C-I (APOC1), clusterin (CLU), inter-alpha-trypsin inhibitor 
heavy chain H4 (ITIH4), and leucine-rich alpha-2-glycoprotein (LRG1), was 
constructed. These proteins showed the differentially expressed levels (p-




value of 0.810 and high prediction rates in both groups (95.5% and 61.7% in 
response and recurrence groups, respectively). To verify the 6-marker panel, 
we further applied MRM analysis with independent patient samples (n=64), 
i.e. response group (n=43) and recurrence group (n=21), as a test set. We 
demonstrated that 6 marker proteins showed the correlated expression patterns 
as in a training set with statistical significance (p-value < 0.05). We propose 
that these proteins can serve as diagnostic signatures to identify the recurrence 
in GC patients and our quantitative MRM assay based serum biomarker 
development platform could serve as a valuable tool in the clinical biomarker 
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1.  Introduction 
Gastric cancer (GC) is the fourth most common cancer type representing the 
second leading cause of cancer-related mortality worldwide (Nagini 2012, 
Carcas 2014, Ferro, Peleteiro et al. 2014) and GC patients have a relatively 
poor prognosis, especially the patients of late pathologic stage with a less than 
35% of 5-year survival rate (Yamazaki, Oshima et al. 1989). It has been 
reported that some risk factors of GC is associated with presence of 
Helicobacter pylori infection (Parsonnet, Friedman et al. 1991), age (>60 
years), a history of stomach disorders or GC, accumulation of genetic 
alteration of multiple genes (Holian, Wahid et al. 2002), and the imbalance 
between cell proliferation and apoptosis (Zhou, Wong et al. 2001). Although 
there are some clinical diagnostic biomarkers in GC, such as the 
carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA 19–9), and 
carbohydrate antigen 72–4 (CA72–4), they are not specific and sensitive 
enough (Ebert and Röcken 2006) for monitoring the disease recurrence. 
Despite improvements in modern curative surgery and/or postoperative 
chemo-radiotherapy including adjuvant treatments for GC, the majority of GC 
patients (~55%) suffer from local, regional or distant recurrence. In the early 
stages of GC patients are asymptomatic, and it is difficult to control the 
malignancy rate through early diagnosis and motivational therapy. Therefore, 
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it is important to find diagnostic biomarkers in GC that would help to 
understand of GC recurrence mechanisms and develop the effective clinical 
application. 
Proteomics-based biomarker development platform using clinical patient’s 
specimen sources has been rapidly evolved and can help to discover the 
accurate diagnostic and/or prognostic biomarkers (McDonald and Yates 2002, 
Schiess, Wollscheid et al. 2009, Frantzi, Bhat et al. 2014). Specifically, current 
advancements in multiple reaction monitoring (MRM) approach along with 
sensitive, selective, multiplexing and through-put analytical features could be 
able to implement for accurate quantification of biomarker candidates using 
triple quadrupole (QqQ) LC-MS instrumentation (Parker and Borchers 2014). 
Furthermore, a highly reproducible advance of MRM approach could result in 
reliable biomarkers that are clinically applicable for disease diagnosis and/or 
prognosis. 
A general workflow of proteomics-based biomarker development platform is 
composed of two strategies including discovery and verification/validation 
stages. In discovery stage, a global proteomic profiling analysis is performed 
to determine the biomarker candidate proteins which show differentially 
expressed levels in control and case groups by a global proteomic profiling 
analysis. In validation stage, selected biomarker candidates are verified and/or 
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validated using the large cohort patient samples using the quantitative MRM 















Figure 1. General workflow of proteomics-based biomarker development 
platform. 
In the discovery, mass spectrometry analysis was performed to identify the 
differentially expressed proteins (DEPs) and then validated them by statistical 
and bioinformatics analysis tools to come up with the potential biomarker 
candidates. In verification and/or validation stage, selected biomarker 
candidates were verified using the large cohort patient samples by performing 





Most recently, several studies have attempted to investigate the potential 
diagnostic GC biomarkers using multiple proteomic strategies, such as matrix-
assisted laser desorption/ionization (MALDI) analysis, isobaric tag for relative 
and absolute quantitation (iTRAQ) method, and MRM analysis. Using a 
combination of proteomic techniques, apolipoprotein C-I (APOC1), 
apolipoprotein C-III (APOC3), and prothrombin (F2) were identified as 
potential serum biomarkers for GC with both high sensitivity (>89.9%) and 
specificity (>71.0%) (Cohen, Yossef et al. 2011). In addition, four proteins 
including afamin (AFM), clusterin (CLU), vitamin D-binding protein (VTDB) 
and haptoglobin (HP) were detected as biomarkers for different stages of 
gastric cancer (Humphries, Penno et al. 2014). These studies demonstrate that 
proteomics-based biomarker development platform can identify the potential 
GC biomarkers by using a large cohort of clinical patient samples. 
Furthermore, several studies recently have attempted to investigate the GC 
recurrence mechanisms by discovering the early diagnostic biomarkers, 
however, the exact reasons and key factors are still elusive (D'Angelica, Gonen 
et al. 2004, Yong, Yang et al. 2012, Spolverato, Ejaz et al. 2014, Wu, Liu et al. 
2014). Therefore, there is a need to find the prognostic biomarkers for 
monitoring the GC recurrence, which could ultimately help to extend GC 
patient’s overall survival rate.  
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On the basis of the clinical significance of GC recurrence, we have established 
the serum biomarker development platform for identification of GC 
recurrence with MRM-based proteomic approach using GC patient serum 
samples. In this study, we especially applied to generate the multi-biomarker 
panel for overcome the limitations of single biomarkers, which often have 
inadequate predictive value and/or poor expression in particular patient 
samples. We discovered 94 biomarker candidates by integrative proteomic 
approach and verified them in the two groups; i.e. a training set (n=180) and a 
test set (n=64), using MRM analysis. To improve the discriminatory power, 
we constructed the 6-marker panel by combining several biomarker candidates 
which showed an AUC value of 0.810 and high prediction rates in two groups 
(95.5% and 61.7% in response and recurrence groups, respectively). Our 
quantitative MRM-based serum biomarker development platform enabled to 
verify the promising multi-biomarker panel of GC recurrence which may 
contribute to identify the GC response and recurrence patients by prediction 






2.  Material and Methods 
2.1.  Reagents  
HPLC grade acetonitrile (ACN) and water were purchased from J.T Baker 
(Phillipsburg, NJ, USA). Formic acid (FA), urea, dithiothreitol (DTT), 
iodoacetamide (IAA), and ammonium bicarbonate were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Sep-pak C18 cartridges were from 
Waters (Milford, MA, USA). Sequencing grade modified porcine trypsin were 
obtained from Promega (Madison, WI, USA). SIS peptides containing a single 
amino acid labeled with 13C and 15N were synthesized at crude levels from JPT 
(Berlin, Germany). 
 
2.2.  Study population 
Between November 2004 and April 2008, 248 GC patients were recruited to 
the study at Samsung Medical Center (Seoul, Korea). The following criteria 
were adopted for patient groups in this study; 1) histologically confirmed 
adenocarcinoma of the stomach, 2) D2 lymph node dissection, 3) Eastern 
Cooperative Oncology Group performance status of 0 or 1, 4) adequate 
function of major organs including cardiac, hepatic, and renal, and 5) adequate 
bone marrow function (hemoglobin > 10g/㎗; absolute neutrophil count [ANC] 
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≥ 1,500/㎕; platelet count ≥ 100,000/㎕). Patients with coexisting 
malignancies or who were unable to tolerate chemotherapy due to other 
systemic illnesses were excluded from the study. Eligible 248 GC patients 
were randomly assigned to receive the adjuvant chemotherapy with 
capecitabine plus cisplatin (XP) and XP plus radiotherapy with capecitabine 
(XPRT). The XP treatment was repeated every 3 weeks with six cycles of 
capecitabine 1,000 mg/m2 twice a day on days 1 to 14 and cisplatin 60 mg/m2 
on day 1. GC patients assigned to XPRT treatment, radiotherapy 45 Gy 
concurrently with 825 mg/m2 twice a day was given after the completion of 
two cycles of XP, followed by two additional cycles of XP. Radiotherapy was 
fractionated to 1.8 Gy daily, 5 days a week, over 5 weeks. All 248 patients 
were adhered to the same schedule of the median follow-up duration of 7 years 
after completion of study treatment. Disease-free survival (DFS) was 
measured from the date of surgery until death, recurrence, second primary 
tumor, whichever occurred first. All patient serum samples were collected 4-
week after D2 lymph node dissection (Park, Sohn et al. 2015). 
 
2.3.  Serum sample preparation 
All 248 patient’s blood samples were centrifuged immediately at 2,000 g for 
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10 minutes to fractionate the serum. The resulting supernatant was aliquoted 
(50 – 100 ㎕) and stored at -80℃ until analysis. For global proteomic analysis, 
serum samples were immunodepleted of fourteen high-abundant proteins 
(albumin, antitrypsin, IgA, IgG, IgM, transferrin, haptoglobin, fibrinogen, 
alpha2-macroglobulin, alpha1-acid glycoprotein, apolipoprotein AI, 
apolipoprotein AII, complement C3, and transthyretin) using a MARS Hu-14 
column (Agilent Technologies, Santa Clara, CA) equipped with an Ultimate 
3000 HPLC system (Thermo Fisher Scientific, San Jose, CA). Crude serum 
samples were diluted with buffer A and filtered through a 0.22 ㎛ spin filter 
at 16,000 g at room temperature for 2 minutes to remove particulates. Diluted 
serum samples were injected at 0.125 ml/min and flow-through fraction 
containing the low-abundant proteins was collected. Depleted serum samples 
were concentrated by a 3 kDa molecular weight cutoff (MWCO) filter. 
Depleted serum protein concentration was measured using the Micro BCA 
protein assay kit (Thermo Scientific, Rockford, IL). Equal amounts of proteins 
from each group were separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) with 4 ~ 12% Bis-Tris Gel (Novex NUPAGE 
electrophoresis system, MES running buffer) (Invitrogen, Carlsbad, CA, USA) 
and stained with Coomassie Brilliant Blue (Sigma-Aldrich). Each gel lane was 
cut into nine pieces and subjected to in-gel tryptic digestion following the 
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general protocol. Briefly, excised protein bands were destained, reduced with 
20 mM DTT at 60℃ for one hour and then alkylated with 55 mM 
iodoacetamide at room temperature for 45 minutes in the dark. After 
dehydration with ACN, the proteins were digested with 13 ng/㎕ sequencing 
grade modified trypsin (Promega, Madison, WI, USA) in 50 mM ammonium 
bicarbonate overnight at 37° C. Peptides were extracted from the gel slices 
with 50% (v/v) ACN in 5% (v/v) formic acid (FA). The eluates were dried 
under a Centrivap concentrator (Labconco, Kansas City, MO) and stored at -
20°C until used. 
For MRM-MS analysis, serum samples were immunodepleted of six high-
abundant proteins (albumin, IgA, IgG, transferrin, haptoglobin, and 
antitrypsin) using a MARS Hu-6 column equipped with HPLC system as 
previoulsy described. Protein was reduced with 6M urea and 10mM DTT, and 
alkylated with 30 mM iodoacetamide. The sample was then diluted to 1M urea 
with 50mM ammonium bicarbonate, and sequencing grade modified trypsin 
was added 1:50 (trypsin:protein) ratio and incubated overnight at 37°C. 
Peptides were eluted with 50% (v/v) ACN in 0.1% (v/v) FA and then desalted 
using Sep-pak C18 cartridges. Desalted peptides were lyophilized under a 





2.4.  Mass spectrometry analysis 
Extracted peptide samples were suspended in 0.1% FA and separated on a 
PepMapTM RSLC C18 column (Thermo Fisher Scientific, San Jose, CA) with 
a linear gradient of 2~38% solvent B (0.1% FA in ACN) in for 160 minutes at 
a flow rate of 300 nl/min. Samples were analyzed in duplicate on a Q-Exactive 
(Thermo Fisher Scientific, San Jose, CA) hybrid quadrupole-Orbitrap mass 
spectrometry, interfaced with Ultimate 3000 HPLC system (Thermo Fisher 
Scientific, San Jose, CA). The spray voltage was set to 2.0 kV and the 
temperature of the heated capillary was set to 250°C. The Q-Exactive was 
operated in a data-dependent mode with one survey MS scan followed by ten 
MS/MS scans and a dynamic exclusion time of 30 seconds. The full scans 
were acquired in the mass analyzer at 300 ~ 1400 m/z with the resolution of 
70,000 and the MS/MS scans were obtained with the resolution of 17,500 by 
using a normalized collision energy (NCE) of 27% for high energy collisional 
dissociation (HCD) fragmentation. The automatic gain control (AGC) target 
was set to 1e5, maximum injection time was 120 ms and the isolation window 




2.5.  Database search 
Collected MS/MS data were converted into mzXML files through the Trans 
Proteomic Pipeline (version 4.5) software and searched against the decoy 
uniprot Human database (June 2014, 313072 entries) for the estimation of the 
false discovery rate (FDR) with the SEQUEST (Thermo Fisher Scientific, 
version 27) program in the Proteome Discoverer™ (Thermo Fisher Scientific, 
version 1.4) search platform. Full tryptic specificity and up to two missed 
cleavage sites were allowed; mass tolerances for precursor ions and fragment 
ions were set to 10 ppm and 0.5 Da, respectively; fixed modification for 
carbamidomethyl-cysteine and variable modifications for methionine 
oxidation were used. The Scaffold software package (version 4.6.2, Proteome 
Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identification. All proteins with a ProteinProphet probability ≥ 99% 
and a PeptideProphet probability ≥ 95% were identified (Nesvizhskii, Keller 
et al. 2003). 
 
2.6.  Relative protein quantification 
Relative protein quantification was accomplished using the label-free 
technique, spectral counting. The MS/MS data were normalized to compare 
abundances of proteins between two groups using Scaffold software. The 
normalized spectral counts from duplicate analyses of a control group and an 
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experimental group were compared using the R program (version 2.15) with 
power law global error model (PLGEM) software 
(http://www.bioconductor.org), a statistical analysis software package in order 
to identify DEPs with statistically significant protein changes (signal-to-noise 
ratio (S/N) and p-value) (Pavelka, Fournier et al. 2008). 
 
2.7.  Selection of MRM peptide transitions 
MRM peptide transitions were determined using two scan modes; Unbiased 
Q3-ion monitoring (Cho, Koo et al. 2014): The unbiased Q3-ion monitoring 
assay was performed using MRM mode with the following steps; 1) most 
intense five fragment y and/or b ions were selected from both Q-exactive 
MS/MS spectra and PeptideAtlas database of target peptides, 2) dwell time of 
each transition was set to 5 ms and Q1/Q3 transitions were monitored with a 
unit resolution mass window (0.7 FWHM, full width at half maximum), and 
3) chromatographic elution profiles of each transition ion and estimation of 
chromatographic peak area were carried out using Mass Hunter Quantitative 
Analysis (MHQA) software (version B.6.0, Agilent Technologies). Agilent’s 
MassHunter Optimizer software: An Agilent’s MassHunter Optimizer 
software was utilized with synthetic peptides with the following steps; 1) 
doubly and triply charged precursor ions were selected from each target 
peptide, 2) theoretical fragment y ions were selected from each target peptide, 
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3) selected Q1/Q3 transitions were monitored with ten different collision 
energies (5 ~ 50 V) using MRM mode, and 4) estimation of chromatographic 
peak area were carried out using MHQA software and most intense five 
transitions were selected. 
 
2.8.  AuDIT analysis for determination of accurate and precise MRM 
transitions 
A total of 228 SIS peptides corresponding initial MRM target peptides were 
synthesized at 12 nmol. Stock solutions were prepared at 100 pmol/㎕ with 
30% ACN/0.1% FA and further diluted to 200 fmol/㎕ with 0.1% formic acid. 
MRM analysis was performed in triplicate with a total of 1824 MRM 
transitions using an equimolar mixture (50fmol) of the 228 SIS peptides 
spiked into 5 ㎍ of digested pooled serum samples. For the 3-MRM data set, 
data integration and AuDIT analysis were performed using Skyline and 
QuaSAR program. Briefly, AuDIT uses the p-value of t-test and the coefficient 
of variation (CV) of the ratio of analyte’s peak area ratio (PAR) to SIS’s to 
detect problem transitions. Final MRM transitions were determined by two 
thresholds (p-value＜10-5 for t-test and CV ≤ 20% for PAR, respectively) 




2.9.  Functional enrichment of MRM target proteins by STRING 
database 
To evaluate functional enrichment and interactions between final MRM target 
proteins, we used STRING database (version 10.5, http://string-db.org). It 
allows to assign the biological process, molecular function, cellular 
component, and KEGG pathways by FDR scores based on experimental 
repositories, public text collections, and computational prediction methods 
(Szklarczyk, Franceschini et al. 2014).  
 
2.10.  Study design of MRM analysis order with sample randomization 
Randomization of analyzed sample order can prevent the unbiased 
systematical effects for improving molecular biomarker discovery (Qin, Zhou 
et al. 2014). Randomization for injection order of MRM analysis with 180 
individual patient’s samples was performed using True Random Number 
Service (www.random.org). 
 
2.11.  Multiple reaction monitoring analysis 
Peptides were suspended in 0.1% FA and separated on a ZORBAX Eclipse 
Plus C18 column (2.1x150mm id., 1.8-㎛ particle size, Agilent) with a linear 
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gradient of 0~40% solvent B (0.1% FA in ACN) in for 50 minutes at a flow 
rate of 250 ㎕/min. Samples were analyzed on an Agilent 6490 triple 
quadrupole mass spectrometer (Agilent Technologies) interfaced with an 
Agilent 1290 Infinity HPLC system.  
The ion spray capillary voltage and nozzle voltage set to 3500 and 500 V, 
respectively. The drying gas temperature was set to 250°C at 12 L/min, and 
the sheath gas temperature was 350°C at 11 L/min. The nebulizer was set to 
50 psi. The fragmentor voltage and the cell accelerator voltage was set to 380 
V and 5 V, respectively. Both precursor and product ions were monitored with 
a unit resolution mass window (0.7 FWHM) in Q1 and Q3. In the dynamic 
MRM measurement, transitions were acquired during for retention time ±4 
min of corresponding peptide. Chromatographic elution profiles of each 
transition ion and estimation of chromatographic peak area were achieved 
using both MHQA and Skyline software. 
 
2.12.  Statistical analysis  
To identify the significant DEPs in two analyzed sample groups, we performed 
a statistical analysis using MSstats (version 3.8.2) (Surinova, Hüttenhain et al. 
2013, Choi, Chang et al. 2014). In the first step, data preprocessing was 
performed by transforming all transition intensities into log2 values. Then, a 
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constant normalization was conducted on the basis of reference SIS peptide’s 
transitions for all target peptides, which equalized the median peak ratio 
intensities of reference transitions from all target peptides across all MRM 
runs and adjusted the bias to SIS peptide’s signals. Protein-level quantification 
and testing for differential abundance in both response and recurrent groups 
were performed with the linear mixed model (LMM) implemented in MSstats. 
Each protein is tested for abundant differences between two groups. The p-
values were adjusted to control the FDR at a cutoff of 0.05. All proteins with 
a p-value below 0.05 were considered significant. 
Hierarchical clustering (HLC) analysis was conducted with log2-transformed 
peak area’s ratio of significant DEPs to confirm their distribution patterns 
using Multi Experiment Viewer (Version 4.9, http://www.tm4.org/mev/).    
The stepwise logistic regression analysis was performed to generate the multi-
marker panel which contributed to the discriminatory power between two 
analyzed groups (Klecka 1980). The receiver operator characteristic (ROC) 
curves and interactive plots were generated based on DeLong’s method 
(DeLong, DeLong et al. 1988). All analysis was conducted using MedCalc 
software (Mariakerke, Belgium, version 12.2.1.).  
 
2.13.  Evaluation of quantitative linear curves 
Six SIS peptides (EQLTPLIK of APOA2, EFGNTLEDK of APOC1, 
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ASSIIDELFQDR of CLU, ITFELVYEELLK of ITIH4, DLLLPQPDLR of 
LRG1, and ITLLSALVETR of SERPINA3, respectively) were spiked into 5 
㎍ of digested pooled serum samples and serially diluted at 10 concentrations 
(1, 2.5, 5, 10, 25, 50, 100, 250, 500, and 1000 fmol/㎕). All MRM assay were 
analyzed in triplicate and the normalized peak area was used to generate linear 
















3.  Results 
3.1.  Clinicopathologic characteristics of study population 
In this study, we selected a total of 248 GC patients who received D2 lymph 
node dissection at the Samsung Medical Center (Seoul, Korea). All patients 
were randomly assigned, 107 patients (43.1%) to the XP treatment and 141 
patients (56.9%) to the XPRT treatment as described in Material and Method 
2.2 (study population). After median follow-up of 7 years, 70 recurrence 
events (28.2%) occurred and the estimated 5-year DFS rates were 69.0% (172 
patients alive). In total patient population, 58 (23.4%) patients, 88 (35.5%) 
patients, 70 (28.2%) patients and 32 (12.9%) patients were diagnosed as stage 
I, stage II, stage III and stage VI, according to the Joint Committee on Cancer 
Staging System (six edition, 2002), respectively. Clinicopathologic 
characteristics of study population are summarized in Table 1.  
To generate the multi-marker panel, we divided a total of 248 GC patients into 
2 sub-cohorts which were training and test sets. When we selected the number 
of patients in each set, we performed sample size calculation using MedCalc 
software, taking into account the required significance level and power of the 
test based on two required inputs; 1) the hypothesized AUC value over 0.8 and 
2) ratio of sample sizes in negative and positive groups (recurrence group : 
response group = 1 : 2.5). As a result, we selected 184 patients as a training 
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set to construct of multi-marker panel and other 64 patients as a test set to 






















Table 1. Baseline patient demographics and clinical characteristics. 
 Response group (n=135) Recurrence group (n=49) 
Age   
Median (range) 50 (26-75) 54 (34-80) 
Sex   
Male / Female (Male %) 120/58 (67.4%) 53/17 (75.7%) 
Assigned chemotherapy, n (%)   
XP treatment 78 (43.8%) 29 (41.4%) 
XPRT treatment 100 (56.2%) 41 (58.6%) 
Primary tumor location, n (%)  
Cardia 8 (4.5%) 3 (4.3%) 
Fundus 1 (0.6%) 0 (0.0%) 
Body 100 (56.1%) 30 (42.9%) 
Antrum 68 (38.2%) 36 (51.4%) 
Angle 1 (0.6%) 1 (1.4%) 
*Pathological stage, n (%)  
IB 54 (30.3%) 4 (5.7%) 
II 74 (41.6%) 14 (20.0%) 
III 42 (23.6%) 28 (40.0%) 
IV 8 (4.5%) 24 (34.3%) 









3.2.  Overall scheme of serum biomarker development for gastric 
cancer recurrence using proteomic approach 
In this study we aimed to find multi-biomarker panel for GC recurrence 
patients who received chemotherapy, i.e. XP treatment or XPRT treatment, 
after D2 lymph node dissection. As shown in Figure 2, we first selected a set 
of 330 proteins as initial biomarker candidates via integrative proteomic 
approach using three independent strategies (global profiling, public database, 
and in-house dataset from EOGC). We then performed the preliminary MRM 
and AuDIT analysis to determine final MRM targets which showed a reliable 
detectability with an accurately and precisely quantitative manner in our QqQ 
LC-MS system. As a result, 135 peptides derived from 94 proteins were 
determined as final biomarker candidates for identification of recurrence in 
gastric cancers using MRM analysis. To generate the multi-biomarker panel 
for identification of GC recurrence, we divided all individual patient samples 
in two groups; 1) GC patients who subsequently developed the recurrence 
events as a recurrence group and 2) their controls who showed survival 
outcome as a response group compared to the recurrence group. 
We first applied multiplexed-MRM analysis with a training set (n=180) and 
measured the differentially expressed levels of 94 biomarker candidates 
between the response (n=133) and recurrence (n=47) groups. We identified 65 
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DEPs which showed the quantitative differences in the two groups with a 
statistically significant value (p-value < 0.05) by MSstats analysis. We then 
constructed multi-biomarker panel by combination of these 65 DEPs to obtain 
the best model which could discriminate the two groups. Finally, we further 
performed multiplexed-MRM analysis with a test set (n=64) to demonstrate if 
the constructed multi-biomarker panel had a reproducible performance to 






Figure 2. Overall scheme of serum biomarker development for 
identification of recurrence in gastric cancers.  
In the discovery stage, initial biomarker candidates for identification of 
recurrence in gastric cancers were selected via integrative proteomic 
approaches including public data mining, EOGC data mining, and proteomic 
profiling of study GC patient serum samples. Next, the preliminary and AuDIT 
MRM analysis were performed to determine final MRM target proteins 
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showing the reliable quantitative results in MRM analysis.  
In the validation stage, multiplexed-MRM analysis was performed with the 
training set (n=180) and constructed a multi-biomarker panel by statistical 
analysis. Finally, independent test set (n=64) was analyzed by multiplexed-



















3.3.  Determination of potential serum biomarker candidates for 
identification of recurrence in gastric cancers 
To establish the serum biomarker discovery platform for identification of GC 
recurrence using MRM analysis, we first determined reliable biomarker 
candidates which may have the potential prognosis for GC recurrence by a 
comprehensive proteomic approach. This strategy is composed of three 
independent approaches as follows; 1) a knowledge-based approach with 
global data mining of previously reported protein biomarkers involved in GC, 
2) a proteomic profiling analysis using early onset gastric cancer (EOGC) 
patient samples who may suffer GC recurrence with an increased risk due to 
their genetic abnormality, and 3) a global proteomic profiling analysis using 
pooled study serum samples (n=2) who showed extremely DFS values from 
each group to identify the differentially expressed serum proteins between the 
two groups.  
1) It has been well documented that a global data mining with previously 
reported biomarker proteins and/or proteomic data is a prerequisite approach 
for evaluation of proteomics-based biomarker discovery platform (Killcoyne, 
W Deutsch et al. 2012, Younesi, Toldo et al. 2012, Griss, Perez‐Riverol et al. 
2015). We screened the known potential biomarkers for GC with numbers of 
literatures which have been published after 2009 (Qiu, Yu et al. 2009, 
Lastraioli, Raffaella Romoli et al. 2012, Li, Zhang et al. 2012, Lin, Huang et 
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al. 2012, Leal, Assumpção et al. 2014, Tsai, Wang et al. 2014, Wu, Cheng et 
al. 2014, Elimova, Wadhwa et al. 2015, Jin, Jiang et al. 2015, Mi, Ji et al. 2016). 
In addition, we obtained biomarker candidates from the public database (A 
Database of Human Gastric Cancer, DBGC) which integrates various human 
GC related data resources (Wang, Zhang et al. 2015) 
(http://bminfor.tongji.edu.cn/dbgc/index.do). Through these approaches, we 
found that 306 proteins were previously reported as GC-associated proteins. 
Since our aim was to investigate serum biomarker proteins for identification 
of GC recurrence, we then sorted out 306 proteins using both Plasma Proteome 
database (http://www.plasmaproteomedatabase.org/) and Secreted Protein 
Database (http://spd.cbi.pku.edu.cn/). As a result, 146 serum proteins were 
selected potential biomarker candidates for GC recurrence. 
2) Early onset gastric cancer (EOGC) is defined as gastric cancer presenting 
at the age of 45 or younger (Milne, Sitarz et al. 2007, Milne and Offerhaus 
2010). Although rare proportion (approximately 10%) presenting with GC 
states earlier than 45 years, it is well known that EOGC patients usually show 
poor outcome with GC recurrence (Yoo, Noh et al. 2000, Otsuji, Kuriu et al. 
2004, Kim, Lee et al. 2014). Since the genetic alterations of EOGC patients 
present different patterns compared to older patients, it is importantly thought 
that unraveling genetic mechanisms of EOGC can provide vital information 
of molecular pathway associated with GC (Maehara, Emi et al. 1996, Rugge, 
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Busatto et al. 1999, Haruma, Komoto et al. 2000). In this study, we selected 
biomarker candidates for GC recurrence from previously global proteomic 
profiling data using tumor and adjacent normal tissues collected from three 
different EOGC patients (Park, Park et al. 2015). The proteins with p-value < 
0.05 at least in one of the three tissue pairs were identified as DEPs and a total 
of 118 DEPs were determined as biomarker candidates for GC recurrence.  
3) Although it is important to take advantage of previously reported 
biomarkers for design of biomarker development study using proteomic 
approach, the most desirable way is to utilize actual experimental LC-MS/MS 
profiling datasets from the given biological sample matrices because the 
detectability of biomarker candidates is a critical factor for accurate 
quantification by MRM analysis. In this study, we employed global proteomic 
profiling by LC-MS/MS analysis using study serum samples obtained from 
GC response and recurrence patient groups to identify the DEPs between two 
analyzed groups (Figure 3). Initially, we selected two patient samples from 
each group with representing extremely different disease free survival (DFS) 
values to observe the definite quantitative abundances of serum proteins in the 
two groups. We then carried out the serum-pooling strategy (n=2) of each 
group, followed by the depletion of highly abundant proteins, SDS-PAGE 
protein fractionation, and mass spectrometry analysis. Briefly, an equal 
 
29 
volume (30 ㎕) of two patient serum samples from each group was pooled 
separately and immunodepleted of fourteen interfering high abundant proteins 
in order to identify serum proteome with an effectively expanding of the 
dynamic range. To improve proteome coverage and identify low abundance 
proteins, the depleted serum proteins (30 ㎍) from each group were 
subsequently separated on an SDS-PAGE gel and divided into 9 fractions 
(Figure 4) followed by duplicate LC-MS/MS analysis. We identified a total of 
846 proteins (95.0% peptide probability, 99.0% protein probability, minimum 
one peptide, peptide FDR 0.3%) with the Proteome Discoverer software 
(Version 1.4) using a SEQUEST search engine (Figure 5). In addition, we 
compared the biological processes of identified serum proteins between the 
two groups using Scaffold (version 4.6.2) (Figure 6). 
To estimate the significant DEPs between the two groups, we normalized 
spectral counts in both groups using Scaffold and further statistically validated 
by PLGEM analysis to obtain signal-to-noise ratio and p-values for each 
protein quantification. As a result, we identified 82 DEPs that satisfied the 
cutoff for the signal-to-noise ratio (STN ≥2) (Table 2). Among the 82 proteins, 
54 proteins were significantly up-regulated and 28 proteins were down-




Based on our three independent approaches, a total of 330 proteins were 
selected as initial serum biomarker candidates for identification of recurrence 















Figure 3. Overall workflow of a global proteomic profiling analysis using 
study samples. 
First, two patient samples from each group were selected with DFS values and 
then carried out the serum-pooling strategy, the depletion of fourteen highly 
abundant proteins, and SDS-PAGE protein fractionation. Next, duplicate LC-
MS/MS analysis was performed with Q-exactive LC-MS system and database 
search was conducted with the Proteome Discoverer software using a 
SEQUEST search engine. Expression levels of identified proteins were 
normalized with their spectral counts using Scaffold and statistically validated 
by PLGEM analysis to obtain signal-to-noise ratio and p-values to estimate 
the significant DEPs in the two groups. Finally, initial biomarker candidates 





Figure 4. SDS-PAGE fractionation of immunodepleted serum proteins. 
Pooled immunodepleted serum proteins from adjuvant therapy response 
patients (n=2) and recurrence patients (n=2) were separated on a 4 ~ 12% Bis-
Tris gel. After staining with Coomassie brilliant Blue, gel lanes were cut into 
nine pieces as indicated and subjected to in-gel tryptic digestion. Protein 
markers (lane M), serum samples of recurrence group (each 30 ㎍ in lane 1 
and 2, respectively), and serum samples of response group (each 30 ㎍ in 




Figure 5. Venn diagrams of the numbers of identified proteins and 
peptides by LC-MS/MS analysis. 
(A) A total of 846 serum proteins and (B) their corresponding 5286 unique 
peptides were identified by duplicate LC-MS/MS analysis from both 













Figure 6. Functional enrichment of identified serum proteins. 
A total of 846 serum proteins obtained from the two groups were classified 
into biological process subcategories using Scaffold software. Percentage of 
displayed proteins from both recurrence and response groups are shown in red 
















P01009 SERPINA1 Alpha-1-antitrypsin 60.7  0 
P01008 SERPINC1 Antithrombin-III 28.5  0 
P02774 GC Vitamin D-binding protein 25.8  0 
P02790 HPX Hemopexin 25.7  0 
P0C0L5 C4B Complement C4-B 23.3  0 
P00450 CP Ceruloplasmin 21.8  0 
P01024 C3 Complement C3 17.5  0 
P01011 SERPINA3 Alpha-1-antichymotrypsin 17.5  0 
P01042 KNG1 Kininogen-1 11.7  0 
P02746 C1QB Complement C1q subcomponent subunit B 11.0  0 
P36955 SERPINF1 Pigment epithelium-derived factor 10.9  0 
P02749 APOH Beta-2-glycoprotein 1 10.4  0 
P02747 C1QC Complement C1q subcomponent subunit C 10.3  0 
Q06033 ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 10.3  0 
P00738 HP Haptoglobin 8.8  0 
P01031 C5 Complement C5 8.5  0 
P02743 APCS Serum amyloid P-component 7.4  0 
P04114 APOB Apolipoprotein B-100 7.2  0 
P10643 C7 Complement component C7 7.0  0 
P02748 C9 Complement component C9 6.8  0 
P13671 C6 Complement component C6 6.6  0 
P02741 CRP C-reactive protein 6.0  0 
P15169 CPN1 Carboxypeptidase N catalytic chain 5.8  0 
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 5.7  0 
P08603 CFH Complement factor H 5.5  0 
P02765 AHSG Alpha-2-HS-glycoprotein 5.4  0 
Q96PD5 PGLYRP2 N-acetylmuramoyl-L-alanine amidase 4.8  0.001 
E7ETH0 CFI Complement factor I 4.7  0.001 
P06396 GSN Gelsolin 4.4  0.001 
P05543 SERPINA7 Thyroxine-binding globulin 4.3  0.001 
P02745 C1QA Complement C1q subcomponent subunit A 4.2  0.001 
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P04217 A1BG Alpha-1B-glycoprotein 4.2  0.001 
P02750 LRG1 Leucine-rich alpha-2-glycoprotein 4.0  0.001 
P07360 C8G Complement component C8 gamma chain 4.0  0.001 
P07358 C8B Complement component C8 beta chain 4.0  0.001 
A0A087X2C
0 
IGHM Ig mu chain C region 3.9  0.001 
P05546 SERPIND1 Heparin cofactor 2 3.3  0.002 
P00747 PLG Plasminogen 3.2  0.003 
P22352 GPX3 Glutathione peroxidase 3 3.0  0.003 
Q9Y6R7 FCGBP IgGFc-binding protein  3.0  0.003 
P29622 SERPINA4 Kallistatin 2.9  0.003 
P07357 C8A Complement component C8 alpha chain 2.8  0.004 
O00187 MASP2 Mannan-binding lectin serine protease 2 2.7  0.004 
Q8NBP7 PCSK9 Proprotein convertase subtilisin/kexin type 9 2.7  0.004 
P02766 TTR Transthyretin 2.6  0.004 
P36980 CFHR2 Complement factor H-related protein 2 2.5  0.005 
P19827 ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 2.5  0.006 
P22792 CPN2 Carboxypeptidase N subunit 2 2.4  0.007 
Q96IY4 CPB2 Carboxypeptidase B2 2.4  0.007 
P01877 IGHA2 Ig alpha-2 chain C region 2.4  0.007 
P68871 HBB Hemoglobin subunit beta 2.4  0.007 
P29320 EPHA3 Ephrin type-A receptor 3 2.3  0.007 
Q6EMK4 VASN Vasorin 2.2  0.008 
P0C0L4 C4A Complement C4-A 2.0  0.008 
P35222 ACTB Actin, cytoplasmic 1 -2.1  0.008 
P80108 GPLD1 Phosphatidylinositol-glycan-specific phospholipase D -2.2  0.007 
P14543 NID1 Nidogen-1  -2.2  0.007 
P43652 AFM Afamin -2.4  0.006 
P02652 APOA2 Apolipoprotein A-II -2.4  0.006 
P02775 PPBP Platelet basic protein -2.5  0.005 
P70232 CHL1 Neural cell adhesion molecule L1-like protein -2.6  0.004 
P02649 APOE Apolipoprotein E -2.6  0.004 
P49747 COMP Cartilage oligomeric matrix protein -3.0  0.003 
P04275 VWF von Willebrand factor -3.1  0.003 
P03952 KLKB1 Plasma kallikrein -3.1  0.003 
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P01860 IGHG3 Ig gamma-3 chain C region -3.3  0.003 
O75473 LGR5 
Leucine-rich repeat-containing G-protein coupled receptor 
5  
-3.5  0.002 
O75882 ATRN Attractin -3.9  0.001 
P00739 HPR Haptoglobin-related protein -4.0  0.001 
A2MYD4 V2-7 V2-7 protein -4.1  0.001 
P02753 RBP4 Retinol binding protein 4, -6.3  0 
Q8N5F4 IGL@ IGL@ protein -6.3  0 
P04004 VTN Vitronectin -6.7  0 
P04196 HRG Histidine-rich glycoprotein -6.7  0 
P19823 ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 -8.9  0 
P07996 THBS1 Thrombospondin-1 -9.7  0 
P01023 A2M Alpha-2-macroglobulin -10.8  0 
P10909 CLU Clusterin -12.1  0 
P02787 TF Transferrin -14.5  0 
P25311 AZGP1 Zinc-alpha-2-glycoprotein -15.0  0 
P02751 FN1 Fibronectin 1 -16.9  0 
P02647 APOA1 Apolipoprotein A-I -30.9  0 












3.4.  Determination of MRM targets by both preliminary MRM and 
AuDIT analysis 
A key step for quantitative MRM analysis is the determination of confident 
and detectable MRM transitions within a QqQ LC-MS system (Gerber, Rush 
et al. 2003, Kirkpatrick, Hathaway et al. 2006). In this study, a set of MRM 
candidate peptides (≥5) for each target protein were selected from 
PeptideAtlas DB (http://www.peptideatlas.org/) following the general 
selection criteria, such as uniqueness to the target proteins, the length of 
peptides (10 ~ 25 amino acids) and the charge states that can be detected 
within the m/z scan window. Next, we selected MRM transition candidates 
(≥5) as their intensity order of each target peptide using both PeptideAtlas DB 
and our global proteomic MS/MS data. With these MRM target candidates, 
we performed preliminary MRM analysis to confirm their reliable 
detectability using the unbiased Q3 ion monitoring method in our QqQ LC-
MS system (Cho, Koo et al. 2014) (Figure 7). As a result, 228 peptides derived 
from 141 proteins were selected our initial MRM targets following the 
selection criteria; at least 5 transitions were detected per target peptide with 
co-eluted chromatographic patterns as showing the S/N ratio above 3 (Figure 






Figure 7. Workflow for determination of MRM transitions.  
MRM target peptides (≥5) for each target protein were selected by 
PeptideAtlas DB. Next, the MRM transitions of target peptides were 
determined by the unbiased Q3 ion monitoring using QqQ LC-MS (Cho, Koo 
et al. 2014). All transitions were confirmed by co-elution patterns of Q3 ions 








Figure 8. Detectability test of MRM target peptides using QqQ LC-MS. 
Four MRM target peptides were analyzed by preliminary MRM analysis with 
selected top 6 highly abundant MRM transitions obtained from PeptideAtlas 
DB. Chromatographic elution profiles of selected MRM transitions were 
generated by unbiased Q3 ion monitoring mode using the QqQ LC-MS 
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platform. All of the corresponding MRM transitions of (A) 
GAYPLSIEPIGVR (686.38, MH2+) of CP, (B) ATVVYQGER (511.77, MH2+) 
of APOH, (C) IAQWQSFQLEGGLK (802.92, MH2+) of A2M, and (D) 
EVPLNTIIFMGR (695.38, MH2+) of SERPINC1 are assigned with the same 



















To improve the quantitative performance of MRM analysis as more accurate 
and precise manners, we further performed AuDIT analysis using 228 SIS 
peptides for initial MRM target peptides from preliminary MRM analysis. 
AuDIT analysis can be used to develop the quantitative MRM method as more 
accurate and reliable by identifying the inaccurate and inconsistent transitions 
using SIS peptides (Abbatiello, Mani et al. 2010, Burgess, Keshishian et al. 
2014). Through this approach, we removed both interference and poor 
chromatograms from 228 MRM target peptides with two filter criteria; 1) p-
value＜10-5 for t-test and 2) CV ≤ 20% for PAR. As a result, we determined a 
total of 135 MRM target peptides derived from 94 target proteins of interest 
as final MRM targets which could be confidently measured their abundance 
in our MRM analysis platform (Table 3). Among final MRM target proteins, 
10, 44, 55 proteins were derived from public data mining, EOGC profiling, 
and study sample profiling in our integrative proteomic approach, respectively 
(Figure 9 and Table 3). 
To evaluate biological functions of final MRM target proteins, we used 
STRING database (version 10.5) to interpret the biological processes of 94 
target proteins and confirmed that they were involved in blood coagulation 
and platelet function, immune response, organelle organization and cellular 
function categorizations (Figure 10). 
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Table 3. Final MRM targets by AuDIT analysis. 
Uniprot ID Gene name Peptide sequence Target origin 
Quantitative  
MRM transition 
P04217 A1BG HQFLLTGDTQGR Study sample 686.85/734.34 (y7) 
P01023 A2M LHTEAQIQEEGTVVELTGR Study sample 704.03/674.38 (y6) 
  IAQWQSFQLEGGLK  802.93/978.53 (y9) 
P60709 ACTB DSYVGDEAQSK Study sample 599.76/734.33 (y7) 
Q76LX8 ADAMTS13 FDLELPDGNR EOGC 588.26/558.26 (y5) 
P43652 AFM IAPQLSTEELVSLGEK Study sample 857.47/765.41 (y142+) 
  ESLLNHFLYEVAR  795.92/897.48 (y7) 
P02765 AHSG HTLNQIDEVK Study sample 598.82/958.52 (y8) 
  FSVVYAK  407.23/579.35 (y5) 




  ETLLQDFR  511.27/565.27 (y4) 
P02743 APCS IVLGQEQDSYGGK Study sample 697.35/213.16 (b2) 
P02647 APOA1 LLDNWDSVTSTFSK Study sample 806.90/670.34 (y6) 
  VSFLSALEEYTK  693.86/940.46 (y8) 




  EQLTPLIK /Study sample 471.29/571.38 (y5) 
P04114 APOB FPEVDVLTK Study sample 524.29/450.76 (y82+) 
  TGISPLALIK  506.82/654.45 (y6) 




  EWFSETFQK  601.28/739.36 (y6) 




P02749 APOH ATVVYQGER Study sample 511.77/652.30 (y5) 
  EHSSLAFWK  552.78/267.11 (b2) 
P25311 AZGP1 AGEVQEPELR Study sample 564.29/514.30 (y4) 
  EIPAWVPFDPAAQITK  891.97/770.91 (y142+) 
P06276 BCHE FWTSFFPK EOGC 530.27/244.17 (y2) 
P30043 BLVRB LQAVTDDHIR EOGC 389.88/756.36 (y6) 








P09871 C1S VGATSFYSTCQSNGK EOGC 803.86/881.38 (y8) 
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  SSNNPHSPIVEEFQVPYNK  729.36/620.34 (y5) 
P01024 C3 SNLDEDIIAEENIVSR Study sample 908.95/917.47 (y8) 
P0C0L4 C4A ANSFLGEK Study sample 433.22/680.36 (y6) 
  DSSTWLTAFVLK  684.36/791.50 (y7) 
P0C0L5 C4B ASSFLGEK Study sample 419.72/446.26 (y4) 
  VGDTLNLNLR  557.81/629.37 (y5) 




  GIYGTISR  433.74/533.30 (y5) 
P10643 C7 VLFYVDSEK Study sample 550.28/740.35 (y6) 
  LSGNVLSYTFQVK  728.40/872.45 (y7) 
P07357 C8A LGSLGAACEQTQTEGAK Study sample 860.91/991.47 (y9) 
  HTSLGPLEAK  526.79/218.15 (y2) 
P07360 C8G QLYGDTGVLGR Study sample 589.81/774.41 (y8) 
  SLPVSDSVLSGFEQR  810.92/710.86 (y132+) 




P16070 CD44 YGFIEGHVVIPR EOGC 462.92/510.30 (y92+) 
P12830 CDH1 TIFFCER EOGC 486.73/758.33 (y5) 
P00751 CFB EAGIPEFYDYDVALIK Study sample 921.96/736.87 (y122+) 
  DFHINLFQVLPWLK  885.49/543.33 (y4) 
P08603 CFH SPDVINGSPISQK Study sample 671.35/399.19 (b4) 
  SSNLIILEEHLK  698.40/768.43 (y6) 
P36980 CFHR2 TGDIVEFVCK Study sample 584.29/274.10 (b3) 




  VFSLQWGEVK  596.82/946.50 (y8) 
O00533 CHL1 TTVILPLAPFVR EOGC 663.91/799.48 (y7) 
P10909 CLU ASSIIDELFQDR Study sample 697.35/922.43 (y7) 
P12111 COL6A3 VAVVQYSDR EOGC 518.77/540.24 (y4) 
  ELPSLEQK  472.26/701.38 (y6) 
P00450 CP EYTDASFTNR Study sample 602.27/624.31 (y5) 
  GAYPLSIEPIGVR  686.39/870.50 (y8) 
Q96IY4 CPB2 YSFTIELR Study sample 514.77/631.38 (y5) 
P22792 CPN2 LSNNALSGLPQGVFGK Study sample 801.44/732.40 (y7) 
P01034 CST3 ALDFAVGEYNK EOGC 613.81/780.39 (y7) 
Q01459 CTBS DIIDPAFR EOGC 473.75/490.28 (y4) 
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P27487 DPP4 VLEDNSALDK EOGC 552.28/891.41 (y8) 
P17813 ENG VLPGHSAGPR EOGC 330.85/487.26 (y5) 
P06733 ENO1 IGAEVYHNLK Public DB 381.88/374.24 (y3) 
P00742 F10 TGIVSGFGR EOGC 447.25/523.26 (y5) 
P03951 F11 TAAISGYSFK EOGC 522.77/688.33 (y6) 
  VVSGFSLK  418.75/638.35 (y6) 
P00734 F2 ETWTANVGK EOGC 503.25/488.28 (y5) 
P23142 FBLN1 TGYYFDGISR EOGC 589.78/694.35 (y6) 
  ITYYHLSFPTNIQAPAVVFR  779.75/688.41 (y6) 
P08637 FCGR3A AVVFLEPQWYR EOGC 704.37/749.37 (y5) 
P02671 FGA QLEQVIAK Public DB 464.78/218.15 (y2) 
P02751 FN1 STTPDITGYR EOGC 555.78/609.34 (y5) 
  SYTITGLQPGTDYK  772.39/680.33 (y6) 




P40197 GP5 YLGVTLSPR EOGC 503.29/729.43 (y7) 
P80108 GPLD1 TLLLVGSPTWK Study sample 607.86/675.35 (y6) 
P22352 GPX3 FLVGPDGIPIMR Study sample 657.87/516.30 (y4) 
P06396 GSN TGAQELLR Study sample 444.25/530.33 (y4) 
  AGALNSNDAFVLK  660.35/893.47 (y8) 
P02790 HPX NFPSPVDAAFR Study sample 610.81/480.25 (y92+) 
  LYLVQGTQVYVFLTK  886.50/770.44 (y6) 
P04196 HRG DGYLFQLLR Study sample 562.81/676.41 (y5) 
  DSPVLIDFFEDTER  841.90/1058.44 (y8) 
P17936 IGFBP3 YGQPLPGYTTK EOGC 612.82/666.35 (y6) 
P19827 ITIH1 AAISGENAGLVR Study sample 579.32/815.44 (y8) 
  FAHYVVTSQVVNTANEAR  669.34/775.37 (y7) 
P19823 ITIH2 FYNQVSTPLLR Study sample 669.36/686.42 (y6) 
  FLHVPDTFEGHFDGVPVISK  747.72/872.93 (y162+) 




B2RMS9 ITIH4 SPEQQETVLDGNLIIR Study sample 906.48/685.44 (y6) 
  ITFELVYEELLK  748.92/1006.58 (y8) 
H0YAC1 KLKB1 IAYGTQGSSGYSLR Study sample 730.36/638.30 (y122+) 
  VLTPDAFVCR  589.31/213.16 (b2) 
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P01042 KNG1 QVVAGLNFR Study sample 502.29/677.37 (y6) 
  TVGSDTFYSFK  626.30/1051.47 (y9) 
P13796 LCP1 VYALPEDLVEVNPK EOGC 793.43/1139.59 (y10) 
P08519 LPA GSFSTTVTGR EOGC 506.76/533.30 (y5) 
P02750 LRG1 VAAGAFQGLR Study sample 495.28/748.41 (y7) 
  DLLLPQPDLR  590.34/725.39 (y6) 
P08253 MMP2 VDAAFNWSK EOGC 519.26/823.41 (y7) 
P26927 MST1 AAFCYQIR EOGC 514.75/579.32 (y4) 
  VVGGHPGNSPWTVSLR  554.96/575.35 (y5) 
P13591 NCAM1 FFLCQVAGDAK EOGC 628.31/848.39 (y8) 
Q96S96 PEBP4 VISLLPK EOGC 385.26/244.17 (y2) 
P12955 PEPD STLFVPR EOGC 410.24/518.31 (y4) 
Q96PD5 PGLYRP2 TFTLLDPK Study sample 467.77/224.17 (y2) 
  TDCPGDALFDLLR  746.86/1116.60 (y10) 
P00747 PLG EAQLPVIENK Study sample 570.82/699.40 (y6) 
P02775 PPBP TTSGIHPK Study sample 420.73/638.36 (y6) 
  EESLDSDLYAELR  770.36/1081.52 (y9) 
P07225 PROS1 NNLELSTPLK EOGC 564.82/357.25 (y3) 
P22891 PROZ ENFVLTTAK EOGC 511.78/533.33 (y5) 
O00391 QSOX1 DFNIPGFPTVR EOGC 631.83/472.29 (y4) 
Q5VY30 RBP4 FSGTWYAMAK Study sample 581.27/769.37 (y6) 
  YWGVASFLQK  599.82/849.48 (y8) 




P01011 SERPINA3 ITLLSALVETR Study sample 608.37/775.43 (y7) 
P29622 SERPINA4 LGFTDLFSK Study sample 514.28/710.37 (y6) 
P05543 SERPINA7 NALALFVLPK Study sample 543.34/244.17 (y2) 
P01008 SERPINC1 TSDQIHFFFAK Study sample 670.84/659.36 (y5) 
  EVPLNTIIFMGR  695.38/581.33 (y102+) 
P05546 SERPIND1 TLEAQLTPR Study sample 514.79/685.40 (y6) 
  QFPILLDFK  560.82/294.18 (y2) 




P09486 SPARC LEAGDHPVELLAR EOGC 473.92/589.32 (y112+) 
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Q15582 TGFBI LTLLAPLNSVFK EOGC 658.40/988.58 (y9) 




P02766 TTR AADDTWEPFASGK EOGC 697.81/606.32 (y6) 
P04004 VTN DWHGVPGQVDAAMAGR EOGC 833.89/595.26 (b5) 
  DVWGIEGPIDAAFTR  823.91/947.49 (y9) 


















Figure 9. A venn diagram of 94 MRM target proteins obtained from three 
independent proteomic approaches. 
Each number in the cell represents count of MRM target proteins derived from 
three independent proteomic approaches including public data mining, global 










Figure 10. Functional enrichment of MRM target proteins generated 
from STRING database. 
Biological functions of 94 MRM target proteins related to (A) blood 
coagulation and platelet function, (B) immune response, (C) organelle 




3.5.  Multiplexed-MRM analysis of potential serum biomarkers for 
identification of recurrence in gastric cancers with training set’s patient 
samples 
The most reliable strategy for verification of biomarker candidates by clinical 
proteomic approach is to estimate their abundances with individual samples 
using MRM analysis. In this study, we measured the relative expression levels 
of 94 serum biomarker candidates between the GC recurrence group (n=47) 
and response group (n=133) as a training set. Prior to MRM analysis, we 
randomized the order of MRM runs with a total of 180 samples to avoid the 
possible bias derived from technical MS run variations.  
We conducted the quantitative MRM analysis with individual training set’s 
patient serum samples (n=180) using the pre-determined 876 MRM transitions 
for 135 MRM target peptides derived from 94 target proteins of interest with 
spiked SIS peptides. Figure 11 is a chromatographic trace of 135 MRM 
peptides in GC patient sample. To obtain the quantitative data of each target 
peptide from our MRM analysis, we imported quantitative MRM data into 
Skyline and normalized peak area of target peptides using their corresponding 







Figure 11. Multiplexed-MRM analysis of potential serum protein 
biomarkers for identification of recurrence in gastric cancers. 
Multiplexed-MRM analysis was performed with 135 peptides of 94 target 
proteins with their SIS peptides. Extracted ion chromatograms represent the 







To determine the potential serum biomarkers representing the significant 
expression levels in the GC recurrence group compared to the response group, 
we performed statistical analysis with quantitative MRM results by LMM 
analysis embedded in MSstats. As a result, we identified that 76 target peptides 
derived from 65 proteins which showed the differentially expressed levels 
between the two groups with significantly statistical values (p-value < 0.05) 
(Table 4). We found that the biological functions of these 65 DEPs were 
involved in blood coagulation, immune response, and cellular proliferation. 
We further generated HLC with the log2-transformed peak area’s ratio of 76 
peptides for 65 DEPs to confirm their distribution patterns in analyzed two 













Table 4. Significant *DEPs between the two groups by **LMM analysis 
using MSstats. 
Uniprot ID Gene name Peptide sequence logFC AveExpr Adjusted p-value  
P02775 PPBP TTSGIHPK -2.34 -0.14 4.45E-19 
P27487 DPP4 VLEDNSALDK -1.62 8.18 1.04E-18 
P02652 APOA2 SPELQAEAK -0.92 -3.94 1.04E-16 
P10909 CLU ASSIIDELFQDR 0.75 -0.61 1.97E-16 
P02751 FN1 SYTITGLQPGTDYK -1.12 -0.19 2.33E-14 
P02751 FN1 STTPDITGYR -1.03 -0.46 8.93E-13 
P02750 LRG1 DLLLPQPDLR 0.68 0.72 3.25E-12 
P04004 VTN DWHGVPGQVDAAMAGR 1.31 -0.48 8.14E-12 
P01008 SERPINC1 EVPLNTIIFMGR 1.28 -0.45 1.44E-11 
L8E853 VWF ILAGPAGDSNVVK 0.94 5.20 3.56E-11 
P26927 MST1 AAFCYQIR -0.72 1.09 3.62E-10 
P02743 APCS IVLGQEQDSYGGK -1.78 5.07 1.35E-09 
P02671 FGA QLEQVIAK 1.27 5.52 6.10E-09 
O00391 QSOX1 DFNIPGFPTVR -1.35 1.95 6.74E-09 
P22352 GPX3 FLVGPDGIPIMR 0.99 3.40 1.54E-08 
P08253 MMP2 VDAAFNWSK -0.99 7.20 1.88E-08 
Q06033 ITIH3 SLPEGVANGIEVYSTK 0.64 1.03 2.15E-08 
P02766 TTR AADDTWEPFASGK -0.58 -2.38 3.51E-08 
P01031 C5 GIYGTISR 0.81 -0.63 4.28E-08 
P19823 ITIH2 FLHVPDTFEGHFDGVPVISK 0.44 -2.09 5.47E-08 
P06702 S100A9 NIETIINTFHQYSVK -0.95 1.19 9.41E-08 
P01042 KNG1 TVGSDTFYSFK 0.48 -1.95 1.67E-07 
P04004 VTN DVWGIEGPIDAAFTR 0.33 -3.10 2.29E-07 
Q5VY30 RBP4 FSGTWYAMAK 1.26 0.62 2.39E-07 
P05156 CFI HGNTDSEGIVEVK 0.35 0.06 2.40E-07 
P06276 BCHE FWTSFFPK -0.38 0.54 5.56E-07 
P00450 CP GAYPLSIEPIGVR 0.52 -2.70 1.26E-06 
P00747 PLG EAQLPVIENK 0.29 -0.98 1.89E-06 
P04196 HRG DSPVLIDFFEDTER 0.81 -4.52 3.68E-06 
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P08603 CFH SPDVINGSPISQK 0.42 -1.06 4.21E-06 
P43652 AFM ESLLNHFLYEVAR 0.38 0.38 6.83E-06 
P04114 APOB TGISPLALIK -0.43 -1.09 7.94E-06 
P36955 SERPINF1 SSFVAPLEK -0.32 1.81 1.41E-05 
P02790 HPX NFPSPVDAAFR -0.38 -4.47 2.84E-05 
P02746 C1QB IAFSATR -1.02 1.60 3.06E-05 
P22891 PROZ VVSGFSLK 0.48 5.32 3.22E-05 
P00734 F2 ETWTANVGK 0.57 0.67 4.34E-05 
P02654 APOC1 EWFSETFQK 0.50 -0.16 5.48E-05 
P02765 AHSG HTLNQIDEVK 0.80 -1.56 6.57E-05 
P02654 APOC1 EFGNTLEDK 0.75 1.48 8.06E-05 
Q15582 TGFBI LTLLAPLNSVFK 0.34 4.57 8.17E-05 
P00751 CFB EAGIPEFYDYDVALIK 0.51 -2.17 0.0002 
P04114 APOB FPEVDVLTK -0.50 2.26 0.0002 
P09486 SPARC LEAGDHPVELLAR 0.81 5.64 0.0002 
P30043 BLVRB LQAVTDDHIR -0.50 4.20 0.0003 
P05546 SERPIND1 QFPILLDFK -0.32 -0.72 0.0004 
P04217 A1BG HQFLLTGDTQGR 0.25 -2.24 0.0004 
P23142 FBLN1 TGYYFDGISR -0.32 1.49 0.0005 
P07357 C8A HTSLGPLEAK 0.25 1.30 0.0005 
P25311 AZGP1 EIPAWVPFDPAAQITK 0.34 0.40 0.0007 
P02774 GC VLEPTLK 0.28 -2.89 0.0007 
P07357 C8A LGSLGAACEQTQTEGAK 0.36 0.79 0.0015 
P07996 THBS1 SITLFVQEDR -0.46 -0.25 0.0015 
P03951 F11 TAAISGYSFK 0.29 4.31 0.0017 
P09871 C1S SSNNPHSPIVEEFQVPYNK -0.40 -0.61 0.0020 
P09871 C1S VGATSFYSTCQSNGK 0.45 -0.12 0.0029 
P12955 PEPD STLFVPR -0.24 5.37 0.0030 
P02765 AHSG FSVVYAK 0.24 -2.96 0.0038 
P16070 CD44 YGFIEGHVVIPR 0.35 2.99 0.0039 
P29622 SERPINA4 LGFTDLFSK -0.16 1.60 0.0059 
P13591 NCAM1 FFLCQVAGDAK 0.34 5.35 0.0070 
Q96IY4 CPB2 YSFTIELR -0.31 1.77 0.0084 
P01023 A2M IAQWQSFQLEGGLK 0.26 -3.89 0.0104 
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P00450 CP EYTDASFTNR 0.22 -0.78 0.0110 
P22891 PROZ ENFVLTTAK -0.28 4.35 0.0110 
P02652 APOA2 EQLTPLIK -0.42 -2.63 0.0118 
P02749 APOH EHSSLAFWK 0.41 -1.90 0.0123 
B2RMS9 ITIH4 SPEQQETVLDGNLIIR -0.25 -2.04 0.0131 
P06396 GSN AGALNSNDAFVLK 0.21 -0.29 0.0158 
P60709 ACTB DSYVGDEAQSK -0.32 5.11 0.0160 
B2RMS9 ITIH4 ITFELVYEELLK -0.51 -2.32 0.0161 
P01011 SERPINA3 ITLLSALVETR -0.21 -3.52 0.0163 
P17813 ENG VLPGHSAGPR 0.14 7.49 0.0202 
P12830 CDH1 TIFFCER 0.22 3.48 0.0233 
O00533 CHL1 TTVILPLAPFVR 0.17 5.76 0.0285 
P08519 LPA GSFSTTVTGR 0.67 5.30 0.0308 
* DEPs : Differentially expressed proteins generated by MSstats analysis. 







Figure 12. Cluster analysis with 65 DEPs in GC response versus 
recurrence groups. 
HLC analysis was conducted with 76 peptides for 65 DEPs (p-value < 0.05) 
in a training set using Multi Experiment Viewer (Version 4.9). The x- and y- 








3.6.  Construction of the multi-biomarker panel for identification of 
GC response and recurrence groups 
In this study, our final goal was to construct the multi-biomarker panel which 
could predict GC patients who have the potential possibility of recurrence 
events. Although 65 proteins showed significant changes in their abundances 
between the two groups, these proteins had the limitations as a single marker 
for identification of GC recurrence with regard to their specificity and 
sensitivity. Therefore, we constructed the multi-biomarker panel by combining 
65 DEPs to improve the discriminatory power for identification of GC 
recurrence and response groups. We performed logistic regression analysis 
using the stepwise method and generated the multi-biomarker panel’s equation 
with 6 proteins including APOA2, APOC1, CLU, ITIH4, LRG1, and 
SERPINA3, which represented the best combination derived from 65 DEPs. 
Among 6 marker proteins, APOA2, APOC1, and other 4 proteins (CLU, 
ITIH4, LRG1, and SERPINA3) were originated from all three integrative 
proteomic approaches, public data mining and EOGC profiling, and study 
sample profiling, respectively. The molecular function of these 6 proteins were 
involved in enzyme inhibitor activity, phosphatidylcholine binding, and lipase 
inhibitor activity, associated with cancer recurrence (Hudler, Kocevar et al. 
2014, Vargas, Moreno-Rubio et al. 2014, Murakami, Kubo et al. 2015). 
Although each protein of 6-marker panel showed a little lower AUC values 
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(AUC=0.550, 0.732, 0.757, 0.512, 0.771, and 0.570 in APOA2, APOC1, CLU, 
ITIH4, LRG1, and SERPINA3, respectively) (Figure 13) as a single marker in 
analyzed patient samples, we found that when the combination of these 
proteins as the multi-biomarker panel, which showed a higher AUC value 
exceeded 0.8 (AUC = 0.810) (Figure 14). More importantly, the 6-marker 
panel also showed a great prediction rate for distinguishing the two groups, 
which could identify 127 of 133 (95.5%) in the response group and 29 of 47 
(61.7%) in the recurrence group (Table 5).  
In addition, we measured the absolute concentration of 6 marker proteins in 
the two groups as in known amounts of their SIS peptides from quantitative 
















Figure 13. ROC curves and interactive plots for independent six marker 
proteins in a training set.  
The normalized peak areas of transitions were compared between GC response 
(n=133) and recurrence (n=47) groups. (A) The AUC value of each protein 
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showed 0.550, 0.732, 0.757, 0.512, 0.771, and 0.570 in APOA2, APOC1, CLU, 
ITIH4, LRG1, and SERPINA3, respectively. (B) The interactive plots were 
represented by the log2-transformed peak area’s ratio (endogenous target 
peptide versus SIS peptide) of 6 proteins with regard to relative concentration, 





















Figure 14. A ROC curve of the constructed 6-marker panel in a training 
set.  
Logistic regression analysis was performed with a combined 6-marker panel’s 
equation value using the stepwise method to generate ROC curve. The AUC 
value of 6-marker panel showed 0.810 which was higher than each protein’s 










Response group Recurrence group Prediction rate 
Response group 127 6 95.49% 
Recurrence group 18 29 61.70% 















Table 6. Absolute concentration of 6 marker proteins in the two groups. 
6-marker panel 
Average concentration (㎍/㎖) 
Response group Recurrence group 
APOA2 238.4 257.7 
APOC1 9.1 16.3 
CLU 54.6 96.2 
ITIH4 133.5 129.5 
LRG1 22.3 38.8 

















3.7.  Verification of the 6-marker panel’s quantitative performance in 
MRM analysis  
To demonstrate the reasonable quantitative performance of the 6-marker panel 
in complex serum matrices by MRM analysis, we generated the quantitative 
linearity curve using their corresponding 6 SIS peptides. This was 
accomplished by measuring the MRM responses at 10 different concentrations 
(1, 2.5, 5, 10, 25, 50, 100, 250, 500, 1000 fmol) of 6 SIS peptides spiked into 
the pooled GC patient serum samples. The quantitative curve resulted in good 
linearity values (R2 = 0.9998, 0.9997, 0.9878, 0.9705, 0.9994, and 0.9951 in 
EQLTPLIK of APOA2, EFGNTLEDK of APOC1, ASSIIDELFQDR of CLU, 
ITFELVYEELLK of ITIH4, DLLLPQPDLR of LRG1, and ITLLSALVETR 
of SERPINA3, respectively) with reproducible CV values in triplicate MRM 
analysis (Figure 15). These results demonstrated that our 6-protein marker 
panel might be measured their abundances with a highly robust and 












Figure 15. Quantitative linearity curves of the 6-protein marker panel 
using their corresponding SIS peptides. 
MRM assay was performed in triplicate at 10 concentrations (1, 2.5, 5, 10, 25, 
50, 100, 250, 500, and 1000 fmol) of 6 SIS peptides (EQLTPLIK, 
EFGNTLEDK, ASSIIDELFQDR, ITFELVYEELLK, DLLLPQPDLR, and 
ITLLSALVETR of APOA2, APOC1, CLU, ITIH4, LRG1, and SERPINA3, 
respectively) spiked in GC patient serum samples. The quantitative curve 
resulted in a linearity of R2=0.9998, 0.9997, 0.9878, 0.9705, 0.9994, and 
0.9951 in (A) APOA2, (B) APOC1, and (C) CLU, (D) ITIH4, (E) LRG1, and 










3.8.  Verification of the 6-marker panel with test set’s patient samples 
by MRM analysis 
To verify the performance of the 6-marker panel, we applied multiplexed-
MRM analysis with independent GC patient samples (n=64), i.e. response 
group (n=43) and recurrence group (n=21), as a test set. In this approach, we 
used the same analyzed conditions such as QqQ LC-MS parameters, MRM 
targets, and randomization of sample analysis order as previously applied in 
the training set.  
With the generated MRM quantitative data from individual test set’s serum 
samples, we performed MSstats analysis whether the 6-marker panel had the 
reproducible performance as in training set’s results. As a result, we observed 
that the 6-marker panel had the correlated expressed patterns compared to 
training set’s results with significantly statistical values (p-value < 0.05) 
(Table 7) suggesting that the 6-marker panel exhibited consistent quantitative 
features in both training and test sets. 
Using all 244 patient’s quantitative MRM data, we also evaluated both AUC 
value and prediction rate of the 6-marker panel based on DFS at 5 years. 
Among a total of 244 GC patients, 169 patients (69.3%) were alive and other 
75 patients (30.7%) were expired at 5 years. Although 6-marker panel did not 
show the significant AUC value (AUC=0.699), the 6-marker panel showed a 
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reasonable prediction rate of 5-year DFS, which could identify 160 of 169 
















Table 7. Comparison of the 6-marker panel between training and test sets. 
Uniprot ID Gene name Peptide sequence 







P02652 APOA2 EQLTPLIK -2.63 0.0117 -2.24 0.0378 
P02654 APOC1 EFGNTLEDK 1.48 8.06E-05 2.07 0.0317 
P10909 CLU ASSIIDELFQDR -0.61 1.97E-16 -0.12 0.0313 
Q14624 ITIH4 ITFELVYEELLK -2.32 0.0161 -4.40 0.0019 
P02750 LRG1 DLLLPQPDLR 0.72 3.25E-12 1.05 0.0406 













4.  Discussion 
In the course of biomarker development for identification of GC recurrence 
patients who received chemotherapy after D2 lymph node dissection, we 
discovered and verified the multi-biomarker panel by quantitative proteomic 
approach using MRM analysis. In the discovery stage, we selected 330 initial 
biomarker candidate proteins by integrative proteomic approach using three 
independent strategies including public DB mining, EOGC profiling, and 
study sample profiling. We performed preliminary MRM analysis with 330 
initial biomarker candidates to confirm their detectability in QqQ LC-MS 
system and selected 228 peptides derived from 141 proteins as first MRM 
targets. Most importantly, we then conducted AuDIT analysis with 228 MRM 
target peptides using their corresponding SIS peptides to determine final 
MRM targets which may have the accurately and reliably quantitative manners 
in MRM analysis. Through these approaches, a set of 135 peptides derived 
from 94 proteins were selected final MRM targets as biomarker candidates for 
identification of GC recurrence. In general, at least two ionisable unique 
peptides and their two or three transitions could be chosen from the tryptic 
digest of the protein of interest for quantification using MRM analysis. In this 
study, 53 proteins were estimated their abundances with one unique target 
peptide, however, we used more than 4 transitions (4~8) for each target peptide 
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to quantify their abundance confidently. For these reasons, we could estimate 
the accurate quantification of 94 target proteins from our MRM analysis. 
In validation stage, we performed the measurement of differentially expressed 
levels of MRM target proteins with 180 individual patient samples, GC 
recurrence group (n=47) and response group (n=133), as a training set. We 
applied a stringent statistical analysis using MRM quantitative data from 
individual samples by MSstats analysis and identified that 65 proteins showed 
differentially expressed levels with significant values (p-value < 0.05) 
between the two groups. However, these proteins have some limitations as a 
single marker for identification of GC recurrence due to their specificity and 
sensitivity. Therefore, we further conducted a logistic regression analysis to 
generate the multi-biomarker panel by combination of these 65 DEPs. As a 
result, we identified the 6-marker panel, comprising of APOA2, APOC1, CLU, 
ITIH4, LRG1, and SERPINA3, which represented a significant AUC value 
(0.810) and high prediction rates for distinguishing two groups (95.5% and 
61.7% in response and recurrence groups, respectively). 
Although the detailed mechanism is less well-known, our 6-protein marker 
panel may be related to GC and/or several cancer recurrence mechanisms. 
Recently, several studies have indicated that apolipoproteins including 
APOA2 and APOC1 are mainly synthesized in the liver and may be involved 
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in GC biology mechanisms triggering programmed cell death (Vanhollebeke 
and Pays 2006, Liu, Pan et al. 2012). Especially APOC1 has been considered 
potential serum biomarker for GC by discriminating GC patients from cancer-
free controls (Cohen, Yossef et al. 2011). APOC1 binds and enhances the 
inflammatory response which promotes tumor development and progression 
and maintains cell survival by anti-apoptotic and proliferation-enhancing 
effects on cancer cells. Also, APOC1 has an inverse relationship with several 
cancers, such as colorectal, breast, lung, and pancreatic cancers (Engwegen, 
Helgason et al. 2006, Takano, Yoshitomi et al. 2008, Fan, Wang et al. 2010, 
Xue, Scarlett et al. 2010). 
CLU is a ubiquitous secretory sulfated glycoprotein and is an inhibitor of 
apoptosis with a cytoprotective function (Zhang, Kim et al. 2005). The 
expression level of CLU is associated with tumor progression as anti-apoptotic 
mediator in bladder, breast, gastric, pancreatic, and prostate cancers (Miyake, 
Hara et al. 2001, Pins, Fiadjoe et al. 2004, Bi, Guo et al. 2009, Yom, Woo et 
al. 2009, Jin, Kim et al. 2012). In the patients with <T2 stage breast cancer, 
CLU overexpression was a significant prognostic factor for recurrence in spite 
of negative lymph node status and postoperative systemic treatment in all 
cases (Yom, Woo et al. 2009). More importantly, overexpression of CLU was 
associated with tumor invasion and metastasis as p53 abnormal expression in 
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GC patients who showed significantly poor prognosis in late stage (Bi, Guo et 
al. 2009). 
ITIH4 is a member of the inter-alpha-trypsin inhibitor (ITI) family and an 
acute-phase reactant elevated in response to interleukin-6 (Piñeiro, Alava et al. 
1999). It is well known that ITIH genes are potential candidates as tumor 
suppressor or metastasis repressor genes (Fries and Blom 2000, Kobayashi, 
Suzuki et al. 2004). Thus, ITIH molecules may serve as potential diagnostic 
markers or therapeutic targets in the malignant setting. In particular, it is 
known that ITIH4 is observed with elevated levels in GC patients associating 
with tumor progression, invasion and metastasis with increased proliferation 
rates (Subbannayya, Mir et al. 2015).  
LRG1 is an oncogene-associated protein which has been clarified vital to 
various cancers such as gastric, leukemia, non-small cell lung, ovarian, and 
pancreatic cancers (Kakisaka, Kondo et al. 2007, Andersen, Boylan et al. 2010, 
Liu, Luo et al. 2012, Wu, Yu et al. 2012, Uen, Lin et al. 2013). The key 
function of LRG1 in cancer states is cellular survival and apoptosis activating 
TFG-beta signaling pathway (Wang, Abraham et al. 2013). Also, LRG1 has 
been previously reported as overexpressed levels in GC patient plasma and/or 
serum samples as associating to promote angiogenesis (Chong, Lee et al. 
2010).   
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The aberrant expression level of SERPINA3 has been observed in various 
human cancers (Cimino, Fuso et al. 2008, Pascal, Vêncio et al. 2009, Gelfand, 
Vernet et al. 2017). SERPINA3 is a member of the serpin super-family of 
protease inhibitors and usually shown up-regulated in cancer patients by 
regulating both cell cycles and apoptosis via activation of MAPK/ERK and 
PI3K/AKT signaling pathways (Yang, Yang et al. 2014).  
Although functional studies are needed to evaluate the 6-marker panel further, 
our MRM results suggested that the 6 marker proteins, which showed the 
differentially expressed levels in GC response and recurrence groups, may 
play important roles in tumor metastasis, invasion, and apoptotic processes 
associated with GC recurrence mechanisms as previously reported. 
Finally, we applied multiplexed-MRM analysis with independent 64 GC 
patient samples, GC recurrence group (n=43) and response group (n=21), to 
verify the 6-marker panel whether it shows the similar quantitative features as 
in the training set. As a result, we found that the 6-marker panel showed the 
correlated expression patterns in test set’s results with significant statistical 
values (p-value < 0.05). In addition, we performed logistic regression analysis 
to measure the 6-marekr panel’s prediction rates in the test set and confirmed 
that this panel could identify 43 of 43 (100.0%) in response group and 0 of 21 
(0.0%) in recurrence group. Although 6-marker panel showed reproducibly 
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expressed patterns in both training and test sets, it could not predict recurrence 
group in the test set. We thought that this negative result may arise from few 
number of recurrence individual samples to obtain the confident statistical 
values in the test set. However, we speculated that these results also indicated 
the positive aspect for GC patients who should select the potential 
chemotherapy treatments after D2 lymph node dissection, because the 6-
marker panel could identify all response group’s patients. 
There are two major limitations in this study. First, although all study serum 
samples were collected, stored, and processed using predefined standard 
operating procedures, we obtained these samples from a single site clinical 
center (Samsung Medical Center, Seoul, Korea). Ideally, the protein biomarker 
validation study should be performed with independent patient cohorts 
collected from multiple clinical centers. Next, we carried out multiplexed-
MRM analysis with limited number of individual patient samples (n=244). 
Especially the ratio of controls (response group, n=176) and matched cases 
(recurrence group, n=68) were restricted to ensure adequate statistical power 
in this study. Based on these limitations, we focused on the technical aspects 
of quantitative MRM assay as a robust biomarker development platform by 
measuring biomarker candidate’s abundances confidently. As a result, 6 
proteins as generated the multi-marker panel achieved CV values less than 20% 
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with an adequate diagnostic AUC value (AUC=0.810).  
In conclusion, we established a quantitative MRM-based serum biomarker 
development platform as high-throughput and reproducible assay which could 
serve as a valuable tool in the biomarker discovery-validation process. 
Through our approach, we could construct the multi-biomarker panel for 
identification of GC recurrence patients. Although further studies should be 
required to validate the 6-marker panel using independent large cohorts 
(n≥500) collected from multiple hospitals, we propose that our data may 
contribute to identify the GC response and recurrence patients who treated 
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6.  Abstract in Korean 
위암은 두 번째로 높은 사망률을 보이는 가장 일반적인 암 중의 
하나이다. 최근 임상 치료 요법 발전에도 불구하고, 전체 위암 
환자의 재발률은 여전히 높게 남아 있다 (~55%). 따라서 위암 
조기 진단 및 예후에 대한 효과적인 임상 치료법을 개발하기 
위해서는 위암 재발 기전의 이해가 중요하다.  
본 연구는 구축된 프로테오믹스 정량분석법 기술인 
다중반응검지법 플랫폼을 이용하여 위암 재발 혈액 바이오마커를 
발굴하는 것에 목적을 두었다. 혈액 바이오마커 발굴 플랫폼을 
구축하기 위하여, 통합 프로테오믹스 분석법 [(1) 이미 보고된 
위암 특이적 혈액 바이오마커 데이터베이스 마이닝, (2) 조기위암 
환자 조직시료를 이용한 프로테오믹스 정성 분석, (3) 위암 환자 
혈액 시료를 이용한 프로테오믹스 정성 분석]을 이용하여 330개 
혈액 단백질을 위암 재발 혈액 바이오마커 1차 후보군으로 
선정하였다.  
선정된 1차 바이오마커 후보군을 대상으로 선행 다중반응검지법 
분석 및 AuDIT 분석을 통해 신뢰성 있게 정량 분석이 가능한 




다중 바이오마커 패널 구축을 위해, D2 림프절 절제술 후 
항암치료를 받은 180명의 위암 환자들을 training set으로 
선정하였고, 이를 두 군 (치료 반응 환자군=133명, 재발 
환자군=47명)으로 분류하여 다중반응검지법 분석을 수행하였다. 
개별 환자들의 다중반응검지법 정량 결과를 추출 후, 통계 분석을 
수행하여 6개 단백질 (APOA2, APOC1, CLU, ITIH4, LRG1, 
SERPINA3)을 다중 바이오마커 패널로 구축하였다. 이 패널은 두 
군에서 통계적 유의미한 값 (p-value < 0.05)을 가지며 유의미한 
발현차이를 보였으며, 0.810의 AUC 값 및 높은 예측도를 
나타내었다 (치료 반응 환자군=95.5%, 재발 환자군=61.7%). 
구축된 다중 바이오마커 패널을 검증하기 위해 독립적인 64명의 
위암 환자 (치료 반응 환자군=43명, 재발 환자군=21명)를 test 
set으로 선정하여 다중반응검지법 분석 및 통계 분석을 수행하였다. 
Training set 결과와 비교하였을 때, 6개 다중 바이오마커 혈액 
단백질이 test set 내에서도 통계적 유의미한 값 (p-value < 




결론적으로, 본 연구를 통해 선정된 6개 단백질들이 위암 환자의 
재발을 확인하는 진단 시그니처로 사용될 수 있으며, 
다중반응검지법 기반 혈액 바이오마커 구축 플랫폼이 임상적 
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